Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I
暂无分享,去创建一个
Jan Nilsson | Sanjay Kaul | S. Kaul | P. Shah | J. Nilsson | B. Cercek | Prediman K. Shah | Bojan Cercek
[1] M. Eriksson,et al. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. , 1999, Circulation.
[2] T. Langmann,et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. , 1999, Biochemical and biophysical research communications.
[3] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[4] A. Lusis,et al. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? , 1998, American journal of human genetics.
[5] N. Miller. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. , 1987, American heart journal.
[6] R. Ross. Atherosclerosis is an inflammatory disease , 1999 .
[7] P. Barter,et al. Molecular mechanisms of reverse cholesterol transport , 1996, Current opinion in lipidology.
[8] R. F. Hoyt,et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase , 1997, Nature Medicine.
[9] J. Berliner,et al. The role of oxidized lipoproteins in atherogenesis. , 1996, Free radical biology & medicine.
[10] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.
[11] E. Rubin,et al. Evidence that apolipoprotein A-IMilano has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[12] P. Wilson,et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.
[13] Jing Zhao,et al. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. , 1993, The Journal of biological chemistry.
[14] M. Corretti,et al. Cholesterol, cholesterol lowering, and endothelial function. , 1998, Progress in cardiovascular diseases.
[15] C. R. Harper,et al. New perspectives on the management of low levels of high-density lipoprotein cholesterol. , 1999, Archives of internal medicine.
[16] A. Callow,et al. Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[17] C. Bisgaier,et al. Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix. , 1993, The Journal of biological chemistry.
[18] R. Lawn,et al. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. , 2000, Biochemical and biophysical research communications.
[19] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[20] A. Reunanen,et al. Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men , 2000, European journal of clinical investigation.
[21] M. Brown,et al. Heart Attacks: Gone with the Century? , 1996, Science.
[22] J. Berliner,et al. Monocyte binding to endothelial cells induced by oxidized phospholipids present in minimally oxidized low density lipoprotein is inhibited by a platelet activating factor receptor antagonist. , 1997, Advances in experimental medicine and biology.
[23] E. Rubin,et al. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. , 1998, Journal of lipid research.
[24] D. Bonnefont-Rousselot,et al. High Density Lipoproteins (HDL) and the Oxidative Hypothesis of Atherosclerosis , 1999, Clinical chemistry and laboratory medicine.
[25] E. Edelman,et al. Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. , 2000, The Journal of clinical investigation.
[26] P. Edwards,et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[27] N. Grishin,et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. , 2000, Science.
[28] A. Tall,et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.
[29] J. Crawford,et al. Of plaques and stones: the SR‐B1 (scavenger receptor class B, type 1) , 1997, Hepatology.
[30] M. Kashyap. Mechanistic studies of high-density lipoproteins. , 1998, The American journal of cardiology.
[31] M. Aviram. Does paraoxonase play a role in susceptibility to cardiovascular disease? , 1999, Molecular medicine today.
[32] A. Lusis,et al. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. , 1997, The Journal of clinical investigation.
[33] M C Phillips,et al. Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[34] P. Wilson,et al. High Density Lipoprotein Cholesterol, Total Cholesterol Screening, and Myocardial Infarction: The Framingham Study , 1988, Arteriosclerosis.
[35] H. Mabuchi,et al. Molecular Genetics of Cholesterol Transport and Cholesterol Reverse Transport Disorders (Familial Hypercholesterolemia and CETP Deficiency) and Coronary Heart Disease , 1994 .
[36] J. Berliner,et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.
[37] P. Denéfle,et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. , 1996, Circulation.
[38] P. Libby,et al. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[39] A. Lusis,et al. Lipoprotein oxidation and gene expression in the artery wall. New opportunities for pharmacologic intervention in atherosclerosis. , 1993, Biochemical pharmacology.
[40] P. Shah,et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. , 1994, Circulation.
[41] J. Viikari,et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. , 1999, Atherosclerosis.
[42] D. Collen,et al. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. , 1997, Circulation.
[43] R. Mahley,et al. DECREASED HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH SIGNIFICANT LIPOPROTEIN MODIFICATIONS AND WITHOUT CLINICAL ATHEROSCLEROSIS IN AN ITALIAN FAMILY , 1980 .
[44] A. Wierzbicki,et al. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. , 2000, Current Medical Research and Opinion.
[45] P. Shah,et al. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. , 1992, Circulation.
[46] J. Berliner,et al. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis : in vitro and In vivo inhibition by WEB 2086. , 1999, Circulation research.
[47] J. Mehta,et al. Inhibition of arterial thrombus formation by ApoA1 Milano. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[48] C. Fielding,et al. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[49] M. McQueen,et al. Reverse cholesterol transport--a review of the process and its clinical implications. , 1997, Clinical biochemistry.
[50] K. Wakitani,et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.
[51] D. Rader,et al. Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus. , 1997, Journal of lipid research.
[52] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[53] A. Tall,et al. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[54] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[55] A. Hamsten,et al. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). , 1997, The American journal of cardiology.
[56] P. Denéfle,et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[57] G. Franceschini,et al. Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. , 1995, Circulation research.
[58] E. Rubin,et al. Cholesteryl Ester Transfer Protein and Atherogenesis , 1997, Annals of the New York Academy of Sciences.
[59] R. Hovorka,et al. Effects of intravenous infusion of lipid-free apo A-I in humans. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[60] R. Stoney,et al. Relation of Plasma Lipid and Apoprotein Levels to Progressive Intimal Hyperplasia After Arterial Endarterectomy , 1992, Circulation.
[61] A. Tall,et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. , 1996, The Journal of clinical investigation.
[62] T. Langmann,et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease , 1999, Nature Genetics.
[63] O. Wiklund,et al. Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. , 1991, European heart journal.
[64] D. Thelle,et al. THE TROMSØHEART-STUDY HIGH-DENSITY LIPOPROTEIN AND CORONARY HEART-DISEASE: A PROSPECTIVE CASE-CONTROL STUDY , 1977, The Lancet.
[65] B. Staels,et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. , 2001, The Journal of clinical investigation.
[66] G. Franceschini,et al. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[67] A. Tall,et al. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. , 1998, Annual review of nutrition.
[68] G. Miller,et al. PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.
[69] M. Navab,et al. Monocyte adhesion and transmigration in atherosclerosis. , 1994, Coronary artery disease.
[70] M. Kashyap. Basic considerations in the reversal of atherosclerosis: significance of high-density lipoprotein in stimulating reverse cholesterol transport. , 1989, The American journal of cardiology.
[71] E. Rubin,et al. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. , 1994, Journal of lipid research.
[72] D. Shih,et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. , 1996, The Journal of clinical investigation.
[73] J. Qiao,et al. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[74] A. Lusis,et al. An Absorbing Study of Cholesterol , 2000, Science.
[75] R. Mahley,et al. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. , 1980, The Journal of clinical investigation.
[76] J. Crouse,et al. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. , 1999, The American journal of cardiology.
[77] S. Kliewer,et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[78] W. Kannel,et al. Lipoproteins, cardiovascular disease, and death. The Framingham study. , 1981, Archives of internal medicine.
[79] A. von Eckardstein,et al. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. , 1998, Atherosclerosis.
[80] V. Fuster,et al. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.
[81] P. Lerch,et al. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. , 1999, Arteriosclerosis, Thrombosis and Vascular Biology.
[82] J. S. Owen,et al. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. , 1997, Atherosclerosis.
[83] P. Shah. Plaque disruption and thrombosis: potential role of inflammation and infection. , 1999, Cardiology in review.
[84] R. Hegele. Paraoxonase genes and disease. , 1999, Annals of medicine.
[85] C. Abbott,et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.
[86] A. Lacko,et al. Physiologic role and clinical significance of reverse cholesterol transport. , 1992, The Journal of the American Osteopathic Association.
[87] A. Boulton,et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[88] J. S. Owen,et al. Role of ABC1 gene in cholesterol efflux and atheroprotection , 1999, The Lancet.
[89] R. Pasternak,et al. Effects of serum lipid levels on restenosis after coronary angioplasty. , 1991, The American journal of cardiology.
[90] V. Fuster,et al. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[91] José A Fernández,et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. , 1999, The Journal of clinical investigation.
[92] J. Gwynne. High-density lipoprotein cholesterol levels as a marker of reverse cholesterol transport. , 1989, The American journal of cardiology.
[93] J. Neaton,et al. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.
[94] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[95] A. Vaughan,et al. ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. , 2000, Current opinion in lipidology.
[96] J. Fruchart,et al. Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk. , 1994, Atherosclerosis.
[97] E. Rubin,et al. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice , 1993, Nature.
[98] O. Stein,et al. Atheroprotective mechanisms of HDL. , 1999, Atherosclerosis.
[99] A. Vaughan,et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. , 1999, The Journal of clinical investigation.
[100] A. Mendez,et al. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. , 1994, The Journal of clinical investigation.
[101] D. Rader,et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. , 1999, Circulation.
[102] G. Fonarow,et al. formation of , 2022 .
[103] J P Matts,et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.
[104] P. Edwards,et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[105] S. Harvey,et al. Structure and function of apolipoprotein A-I and high-density lipoprotein , 2000, Current opinion in lipidology.
[106] J. Piette,et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.
[107] G. Anantharamaiah,et al. Studies of synthetic peptides of human apolipoprotein A-I containing tandem amphipathic alpha-helixes. , 1998, Biochemistry.
[108] A. Tall,et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.
[109] C. Wilhelmsson,et al. Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors. Apolipoprotein A-I levels in male survivors of myocardial infarction. , 1980, Atherosclerosis.
[110] Berger Gm. High-density lipoproteins, reverse cholesterol transport and atherosclerosis--recent developments. , 1984 .
[111] P. Moulin,et al. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism. , 1999, Journal of lipid research.
[112] Y. Saito. Is cholesteryl ester transfer protein (CETP) deficiency atherogenic in familial hypercholesterolemia. , 1998, Internal medicine.
[113] S. Kaul,et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. , 1999, The American journal of cardiology.
[114] J. Slotte. HDL receptors and cholesterol efflux from parenchymal cells. , 1990, European heart journal.
[115] S. Kaul,et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. , 1998, Circulation.
[116] D. Spady. Reverse cholesterol transport and atherosclerosis regression. , 1999, Circulation.
[117] M. Mackness,et al. Low serum paraoxonase: a risk factor for atherosclerotic disease? , 1999, Chemico-biological interactions.
[118] J J Albers,et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.
[119] Bezafibrate Infarction Prevention study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.
[120] A. Czinner,et al. Lipoprotein (a) concentrations as risk indicators for atherosclerosis. , 1991, Archives of disease in childhood.
[121] T. Forte,et al. The role of apolipoprotein A‐l-containing lipoproteins in atherosclerosis , 1994, Current opinion in lipidology.
[122] A. Chapelle,et al. The intrinsic factor–vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein , 1999, Nature Medicine.
[123] J. Breslow,et al. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[124] T. Hayek,et al. HDL Apolipoprotein A-I Attenuates Oxidative Modification of Low Density Lipoprotein: Studies in Transgenic Mice , 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[125] M. Nieminen,et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.
[126] J. Auwerx,et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[127] P. Shah,et al. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. , 1999, Biochemical and biophysical research communications.
[128] J. Genest,et al. High density lipoproteins in health and in disease. , 1999, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[129] P. Kwiterovich. The antiatherogenic role of high-density lipoprotein cholesterol. , 1998, The American journal of cardiology.
[130] S. Hohnloser,et al. Elevated High-Density Lipoprotein Levels Ameliorate Abnormal Vasoconstriction in Early Atherosclerosis , 2005 .
[131] R. Vogel. Coronary risk factors, endothelial function, and atherosclerosis: A review , 1997, Clinical cardiology.
[132] C. Sensen,et al. Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux , 1999, The Lancet.
[133] A. J. Lusis,et al. Pathogenesis of Atherosclerosis , 1964, The American journal of cardiology.
[134] G. Franceschini,et al. Reverse cholesterol transport: physiology and pharmacology. , 1991, Atherosclerosis.
[135] V. Fuster,et al. Role of high density lipoproteins in the regression of atherosclerosis. , 1992, Circulation.
[136] A. Sharrett,et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[137] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[138] A. Zeiher. Endothelial modulation of coronary vasomotor tone in humans. Effects of atherosclerosis and risk factors for coronary artery disease. , 1994, Arzneimittel-Forschung.
[139] P. Durrington,et al. Human serum paraoxonase. , 1998, General pharmacology.
[140] S B Hulley,et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. , 1986, American heart journal.
[141] P. Denéfle,et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. , 1999, Circulation.
[142] S. Yamashita,et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[143] G. Franceschini,et al. Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[144] J. Westman,et al. Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[145] J. Gamble,et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[146] K. Hirata,et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. , 1993, Circulation research.
[147] M. Connelly,et al. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. , 1999, Journal of lipid research.
[148] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[149] J. Qiao,et al. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. , 1997, The Journal of clinical investigation.
[150] D. Rader,et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[151] G. Fonarow,et al. Paraoxonase and coronary heart disease. , 2002, Current opinion in lipidology.
[152] G. Miller. High density lipoproteins and atherosclerosis. , 1980, Annual review of medicine.
[153] A. M. Lefer,et al. Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[154] A. Tall,et al. Cholesteryl ester transfer protein activity enhances plasma cholesteryl ester formation. Studies in CETP transgenic mice and human genetic CETP deficiency. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[155] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[156] P. Durrington,et al. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[157] K. Williams,et al. The response-to-retention hypothesis of atherogenesis reinforced. , 1998, Current opinion in lipidology.
[158] P. Durrington,et al. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification , 1998, FEBS letters.
[159] B. La Du,et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.
[160] E. Rubin,et al. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[161] Helen H. Hobbs,et al. Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.
[162] P. Luoma. Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity. , 1997, Pharmacology & toxicology.
[163] R. Hegele,et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins , 1996, Current opinion in lipidology.
[164] D. Rader. Gene therapy for atherosclerosis , 1997, International journal of clinical & laboratory research.
[165] P. Roheim. Atherosclerosis and lipoprotein metabolism: role of reverse cholesterol transport. , 1986, The American journal of cardiology.
[166] D. Mangelsdorf,et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. , 2000, Science.
[167] E. Rubin,et al. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.
[168] P. Barter. INHIBITION OF ENDOTHELIAL CELL ADHESION MOLECULE EXPRESSION BY HIGH DENSITY LIPOPROTEINS , 1997, Clinical and experimental pharmacology & physiology.
[169] J. Fruchart,et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. , 1987, Atherosclerosis.
[170] S. Kaul,et al. Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II , 2001, Circulation.
[171] M C Phillips,et al. Cell cholesterol efflux: integration of old and new observations provides new insights. , 1999, Journal of lipid research.
[172] C. Abbott,et al. Is paraoxonase related to atherosclerosis. , 1993, Chemico-biological interactions.
[173] The genetic mapping and gene structure of mouse paraoxonase/arylesterase. , 1995, Genomics.
[174] P. Durrington,et al. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation , 1999, The Lancet.
[175] P. Barter. CETP and atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[176] I. Feuerstein,et al. Very low high-density lipoproteins without coronary atherosclerosis , 1993, The Lancet.
[177] S. Kaul,et al. High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization , 2001, Circulation.
[178] P. Edwards,et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. , 1995, Circulation.
[179] K. Saku,et al. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. , 1985, Thrombosis research.
[180] J. Qiao,et al. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. , 1993, Science.
[181] E. Rubin,et al. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. , 1997, Biochemistry.
[182] D. Shih,et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.
[183] S. Horiuchi,et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[184] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[185] Seth M. Klein,et al. Comparison of Class B Scavenger Receptors, CD36 and Scavenger Receptor BI (SR-BI), Shows That Both Receptors Mediate High Density Lipoprotein-Cholesteryl Ester Selective Uptake but SR-BI Exhibits a Unique Enhancement of Cholesteryl Ester Uptake* , 1999, The Journal of Biological Chemistry.
[186] J. Gamble,et al. High Density Lipoproteins (HDL) Interrupt the Sphingosine Kinase Signaling Pathway , 1999, The Journal of Biological Chemistry.
[187] J. Huttunen,et al. The Helsinki Heart Study: central findings and clinical implications. , 1991, Annals of medicine.
[188] T. Rea,et al. Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[189] S. Reddy,et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. , 2000, Journal of lipid research.